Objective: To assess the clinical impact of semaglutide on obesity management among Saudi adults. Methods: This study will employ a cross-sectional research design to assess the clinical impact of semaglutide on obesity management among Saudi adults. Cross-sectional studies allow for the collection of data at a single point in time, providing a snapshot of the prevalence and effectiveness of obesity management with semaglutide within the chosen population. Results: The study included 359 participants. The most frequent gender among them was male (n= 216, 60.2%) followed by female (n= 143, 39.8%). The most frequent age among study participants was 29-39 years (n= 100, 27.9%) followed by 18-28 years (n= 97, 27%). Participants were asked if they used any type of semaglutide. There were 70 participants said yes (19.5%), and 289 participants said no (80.5%). The most frequent type of semaglutide the participants used was Ozempic (n= 55, 78.6%) followed by Saxenda (n= 8, 11.4%) and the least was Mounjaro (n= 3, 11.4%). The most frequent height among them was 1.61-1.70 m (n= 28, 40%) followed by 1.71-1.80 m (n= 18, 25.7). Participants were asked about their weight before taking medication and their weight now. The most frequent weight before taking medication was 76-85 kg (n= 76-85, 37.1%), and the most frequent weight now was 66-75 kg (n= 25, 35.7%). Conclusion: Study results showed that most study participants are overweight according to their BMI. Most commonly don’t use any type of semaglutide. Most of them don’t have type 2 diabetes. In addition, most of study participants had good social connection